Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$136.46 USD
+0.65 (0.48%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $136.61 +0.15 (0.11%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ASND 136.46 +0.65(0.48%)
Will ASND be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
Other News for ASND
Ascendis Pharma Outlines Capital Strategy
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
Ascendant Resources Names New Auditor
Ascendant Appoints McGovern Hurley As Company Auditor
TimesSquare Capital Global Small Cap Q1 2024 Commentary